欧州のターゲットシーケンシング市場：用途別、製品タイプ別、ターゲットエンリッチメント法別、ターゲットキャプチャタイプ別、エンドユーザー別、国別 - 分析と予測（2024年～2033年）

欧州のターゲットシーケンシングの市場規模は、2023年に8億380万米ドルとなりました。

同市場は、2024年から2033年にかけて11.53%のCAGRで拡大し、2033年には23億7,330万米ドルに達すると予測されています。欧州のターゲットシーケンシング市場は競争が激しく、既存企業と新規参入企業が市場シェアを争っています。市場の予想される成長と進化には課題と機会が混在しており、今後数年間はダイナミックかつ急速に変化する市場として注視していく必要があります。

欧州のターゲットシーケンシング市場は、オーダーメイド治療、ゲノム研究、がんや遺伝性疾患の罹患率上昇などの開発により、大幅な増加が見込まれています。臨床診断、医薬品開発、研究用途では、特定のゲノム領域を調べるための正確で安価な技術であるターゲットシーケンシングの利用が増加しています。高解像度のデータをより短時間かつ低コストで得られるため、従来のシーケンス技術よりも支持されています。

同市場は、同地域がヘルスケアの革新に重点を置いている結果成長しており、ゲノム解析やバイオテクノロジー開発への投資がその後押しとなっています。ドイツ、英国、フランスなどの国々では、強力なヘルスケアシステムとゲノム研究への政府助成金により、ターゲットシーケンシング技術の利用が加速しています。さらに、正確な遺伝子解析に大きく依存する個別化医療やコンパニオン診断の需要の高まりからも、この市場は利益を得ています。

とはいえ、法外な初期費用、複雑なデータ解釈、規制上の障壁などの問題は依然として存在します。とはいえ、バイオインフォマティクスと人工知能の融合など、継続的なイノベーションがこれらの問題を解決し、新たな展望を生み出すことが期待されています。欧州のターゲットシーケンシング市場は、臨床および研究分野で受け入れが進んでいることから、ゲノミクスとプレシジョン・ヘルスケアの進展に欠かせない存在になると予想されます。

当レポートでは、欧州のターゲットシーケンシング市場について調査し、市場の概要とともに、用途別、製品タイプ別、ターゲットエンリッチメント法別、ターゲットキャプチャタイプ別、エンドユーザー別、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

第1章 市場

• 動向：現在および将来の影響評価
• ターゲットシーケンシングワークフロー
• 研究開発レビュー
• 規制状況
• 市場力学：概要
  • 市場促進要因
  • 市場抑制要因
  • 市場機会

第2章 地域

• 地域別概要
• 促進要因と抑制要因
• 欧州
  • 地域概要
  • フランス
  • ドイツ
  • 英国
  • スペイン
  • イタリア
  • その他

第3章 市場-競合ベンチマーキングと

• 企業プロファイル
• 今後の見通し
• 競合情勢
  • F. Hoffmann-La Roche Ltd
  • LGC Limited
  • QIAGEN N.V.

第4章 調査手法

List of Figures

• Figure 1: Europe Targeted Sequencing Market, $Million, 2024, 2027, and 2033
• Figure 2: Targeted Sequencing Market (by Region), $Million, 2023, 2027, and 2033
• Figure 3: Europe Targeted Sequencing Market (by Application), $Million, 2023, 2027, and 2033
• Figure 4: Europe Targeted Sequencing Market (by Target Enrichment Method), $Million, 2023, 2027, and 2033
• Figure 5: Europe Targeted Sequencing Market (by Target Capture), $Million, 2023, 2027, and 2033
• Figure 6: Europe Targeted Sequencing Market (by End User), $Million, 2023, 2027, and 2033
• Figure 7: Europe Targeted Sequencing Market (by Product Type), $Million, 2023, 2027, and 2033
• Figure 8: Key Industrial Developments in Europe Targeted Sequencing Market, 2023
• Figure 9: Workflow of Targeted Sequencing
• Figure 10: Targeted Sequencing Market, Number of Patents (by Country), January 2019-February 2024
• Figure 11: Targeted Sequencing Market (by Year), January 2019-February 2024
• Figure 12: France Targeted Sequencing Market, $Million, 2023-2033
• Figure 13: Germany Targeted Sequencing Market, $Million, 2023-2033
• Figure 14: U.K. Targeted Sequencing Market, $Million, 2023-2033
• Figure 15: Spain Targeted Sequencing Market, $Million, 2023-2033
• Figure 16: Italy Targeted Sequencing Market, $Million, 2023-2033
• Figure 17: Rest-of-Europe Targeted Sequencing Market, $Million, 2023-2033
• Figure 18: Share of Strategic Initiatives
• Figure 19: Data Triangulation
• Figure 20: Top-Down and Bottom-Up Approach
• Figure 21: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Europe Targeted Sequencing Market, Opportunities
• Table 3: Europe Targeted Sequencing Market, Trend Analysis
• Table 4: Some Product Launches in the Targeted Sequencing Market
• Table 5: Targeted Sequencing Market, Key Partnerships and Collaborations
• Table 6: Targeted Sequencing Market, Regulatory Landscape
• Table 7: Impact Analysis of Market Navigating Factors, 2023-2033
• Table 8: Comparison Between Types of Next-Generation Sequencing Techniques
• Table 9: Targeted Sequencing Market (by Region), $Million, 2023-2033
• Table 10: Europe Targeted Sequencing Market (by Application), $Million, 2023-2033
• Table 11: Europe Targeted Sequencing Market (by End User), $Million, 2023-2033
• Table 12: Europe Targeted Sequencing Market (by Product Type), $Million, 2023-2033
• Table 13: Europe Targeted Sequencing Market (by Target Enrichment Methods), $Million, 2023-2033
• Table 14: Europe Targeted Sequencing Market (by Type of Target Capture), $Million, 2023-2033
• Table 15: France Targeted Sequencing Market (by End User), $Million, 2023-2033
• Table 16: France Targeted Sequencing Market (by Product Type), $Million, 2023-2033
• Table 17: Germany Targeted Sequencing Market (by End User), $Million, 2023-2033
• Table 18: Germany Targeted Sequencing Market (by Product Type), $Million, 2023-2033
• Table 19: U.K. Targeted Sequencing Market (by End User), $Million, 2023-2033
• Table 20: U.K. Targeted Sequencing Market (by Product Type), $Million, 2023-2033
• Table 21: Spain Targeted Sequencing Market (by End User), $Million, 2023-2033
• Table 22: Spain Targeted Sequencing Market (by Product Type), $Million, 2023-2033
• Table 23: Italy Targeted Sequencing Market (by End User), $Million, 2023-2033
• Table 24: Italy Targeted Sequencing Market (by Product Type), $Million, 2023-2033
• Table 25: Rest-of-Europe Targeted Sequencing Market (by End User), $Million, 2023-2033
• Table 26: Rest-of-Europe Targeted Sequencing Market (by Product Type), $Million, 2023-2033

Introduction to Europe Targeted Sequencing Market

The Europe targeted sequencing market was valued at $803.8 million in 2023 and is expected to reach $2,373.3 million by 2033, growing at a CAGR of 11.53% between 2024 and 2033. The Europe targeted sequencing market is highly competitive, with established companies and new entrants vying for market share. The market's anticipated growth and evolution present a mix of challenges and opportunities, positioning it as a dynamic and rapidly changing landscape to monitor in the coming years.

Market Introduction

The market for targeted sequencing in Europe is expected to increase significantly due to developments in customized treatment, genomic research, and the rising incidence of cancer and genetic disorders. Clinical diagnostics, medication development, and research applications are increasingly using targeted sequencing, a precise and affordable technique for examining particular genome regions. It is favored over conventional sequencing techniques because it may produce high-resolution data in less time and at a lower cost.

The market is growing as a result of the region's strong emphasis on healthcare innovation, which is bolstered by investments in genomics and biotechnological developments. Targeted sequencing technology use is accelerating in nations like Germany, the UK, and France thanks to strong healthcare systems and government funding for genomic research. Additionally, the market gains from the growing demand for personalized medicine and companion diagnostics, which rely heavily on precise genetic analysis.

Nevertheless, issues including exorbitant upfront expenses, intricate data interpretation, and regulatory barriers continue to exist. Nevertheless, it is anticipated that ongoing innovation, such as the fusion of bioinformatics and artificial intelligence, will resolve these issues and create new prospects. The targeted sequencing market in Europe is expected to be crucial to the advancement of genomics and precision healthcare due to its growing acceptance in the clinical and research sectors.

Market Segmentation

Segmentation 1: by Application

• Cancer
• Reproductive Health
• Hereditary Diseases
• Neurological Disorders
• Infectious Diseases
• Cardiovascular Diseases
• Rare Diseases
• Other Applications

Segmentation 2: by End User

• Diagnostic and Clinical Laboratories
• Academic and Research Institutions
• Pharmaceutical and Biotech Companies
• Other End Users

Segmentation 3: by Product Type

• Instruments
• Services
• Kits/Panels and Assays
• Others

Segmentation 4: by Target Enrichment Method

• Hybridization Capture
• Amplicon Sequencing
• Other Target Enrichment Methods

Segmentation 5: by Target Capture

• Targeted DNA Sequencing
• Targeted RNA Sequencing
• Other Types of Target Capture

Segmentation 6: by Country

• Germany
• France
• U.K.
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The Europe targeted sequencing market (by application) has been segmented into detailed segments of the application of targeted sequencing based on applications, including cancer, reproductive health, hereditary diseases, neurological disorders, infectious diseases, cardiovascular diseases, rare diseases, and other applications.

Growth/Marketing Strategy: Constant advancement and innovation to enhance performance and efficiency can enable prominent players to command premium prices while maintaining growth in revenue and volume.

Competitive Strategy: Key players in the Europe targeted sequencing market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe targeted sequencing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations are expected to aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some of the prominent companies in this market are:

• F. Hoffmann-La Roche Ltd
• LGC Limited
• QIAGEN N.V.

Table of Contents

Executive Summary

Scope and Definition

1 Markets

• 1.1 Trends: Current and Future Impact Assessment
  • 1.1.1 Increasing Number of Targeted Sequencing Products and Services in the Market
  • 1.1.2 Increasing Synergistic Partnerships between Market Players
• 1.2 Targeted Sequencing Workflow
• 1.3 Research and Development Review
  • 1.3.1 Patent Filing Trend (by Country, Year)
• 1.4 Regulatory Landscape
• 1.5 Market Dynamics: Overview
  • 1.5.1 Market Drivers
    • 1.5.1.1 Increasing Demand for High Depth of Coverage in Sequencing
    • 1.5.1.2 Cost and Data Management Benefits of Targeted Sequencing as Compared to WGS
  • 1.5.2 Market Restraints
    • 1.5.2.1 Lack of Advanced Genomic Testing Centers
    • 1.5.2.2 Lack of Knowledge about New Genes
  • 1.5.3 Market Opportunities
    • 1.5.3.1 Increasing Use in Clinical Research and Trials for Better Disease Pathogenesis and/or Clinical Relevance
    • 1.5.3.2 Increasing Adoption in Targeted Therapeutics in Oncology

2 Regions

• 2.1 Regional Summary
• 2.2 Drivers and Restraints
• 2.3 Europe
  • 2.3.1 Regional Overview
    • 2.3.1.1 Driving Factors for Market Growth
    • 2.3.1.2 Factors Challenging the Market
  • 2.3.2 Application
  • 2.3.3 Product
  • 2.3.4 France
  • 2.3.5 Application
  • 2.3.6 Product
  • 2.3.7 Germany
  • 2.3.8 Application
  • 2.3.9 Product
  • 2.3.10 U.K.
  • 2.3.11 Application
  • 2.3.12 Product
  • 2.3.13 Spain
  • 2.3.14 Application
  • 2.3.15 Product
  • 2.3.16 Italy
  • 2.3.17 Application
  • 2.3.18 Product
  • 2.3.19 Rest-of-Europe
  • 2.3.20 Application
  • 2.3.21 Product

3 Markets - Competitive Benchmarking &

Company Profiles

• 3.1 Next Frontiers
• 3.2 Competitive Landscape
  • 3.2.1 F. Hoffmann-La Roche Ltd
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 LGC Limited
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 QIAGEN N.V.
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products
    • 3.2.3.3 Top Competitors
    • 3.2.3.4 Target Customers
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast